Do you want to read an article? Please log in or register.
Reduced HDL function in children and young adults with type 1 diabetes
Cardiovascular Risk and DiseasesHeart, Artery and Coronary DiseasesLipid-Lowering Drugs
Related content
Cardiovascular Risk and DiseasesHeart, Artery and Coronary Diseases
Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes
N Engl J Med.
Rawshani A, Rawshani A, Franzén S, Eliasson B, Svensson AM, Miftaraj M, McGuire DK1, Sattar N, Rosengren A, Gudbjörnsdottir S
doi: 10.1056/NEJMoa1608664.
Cardiovascular Risk and DiseasesHeart, Artery and Coronary Diseases
Application of a Lifestyle-Based Tool to Estimate Premature Cardiovascular Disease Events in Young Adults: The Coronary Artery Risk Development in Young Adults (CARDIA) Study
JAMA Intern Med.
Gooding HC, Ning H, Gillman MW, Shay C, Allen N, Goff DC Jr, Lloyd-Jones D, Chiuve S
doi: 10.1001/
Cardiovascular Risk and Diseases
Cardiovascular complications of type 1 diabetes: update on the renal link
Acta Diabetol.
Orchard TJ, Costacou T
doi: 10.1007/s00592-016-0949-7.
Heart Failure
Effects of Vildagliptin on Ventricular Function in Patients With Type 2 Diabetes Mellitus and Heart Failure: A Randomized Placebo-Controlled Trial
JACC Heart Fail.
McMurray JJV, Ponikowski P, Bolli GB, Lukashevich V, Kozlovski P, Kothny W, Lewsey JD, Krum H; VIVIDD Trial Committees and Investigators
doi: 10.1016/j.jchf.2017.08.004.
Heart, Artery and Coronary Diseases
Association of Longitudinal Trajectory of Albuminuria in Young Adulthood With Myocardial Structure and Function in Later Life: Coronary Artery Risk Development in Young Adults (CARDIA) Study
JAMA Cardiol.
Patel RB, Colangelo LA, Reis JP, Lima JAC, Shah SJ, Lloyd-Jones DM
doi: 10.1001/jamacardio.2019.4867.
Cardiovascular Risk and Diseases
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials
Lancet Diabetes Endocrinol
Sattar N, Lee MMY, Kristensen SL, Branch KRH, Del Prato S, Khurmi NS, Lam CSP, Lopes RD, McMurray JJV, Pratley RE, Rosenstock J, Gerstein HC
doi: 10.1016/S2213-8587(21)00203-5
Cardiovascular Risk and Diseases
Effects of glucagon-like peptide-1 receptor agonists on major cardiovascular events in patients with Type 2 diabetes mellitus with or without established cardiovascular disease: a meta-analysis of randomized controlled trials
Eur Heart J.
Marsico F, Paolillo S, Gargiulo P, Bruzzese D, Dell'Aversana S, Esposito I, Renga F, Esposito L, Marciano C, Dellegrottaglie S, Iesu I, Perrone Filardi P
doi: 10.1093/eurheartj/ehaa082.
COMMENTED
Cardiovascular Risk and DiseasesHeart, Artery and Coronary DiseasesHeart FailureMyocardial InfarctionThrombosis and Stroke
Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials
★ 1
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
★ 2
Recommended and commented by
Prof. Dr emer. Josef Flammer, Faculty Member
BMJ
Palmer SC, Tendal B, Mustafa RA, Vandvik PO, Li S, Hao Q, Tunnicliffe D, Ruospo M, Natale P, Saglimbene V, Nicolucci A, Johnson DW, Tonelli M, Rossi MC, Badve SV, Cho Y, Nadeau-Fredette AC, Burke M, Faruque LI, Lloyd A, Ahmad N, Liu Y, Tiv S, Millard T, Gagliardi L, Kolanu N, Barmanray RD, McMorrow R, Raygoza Cortez AK, White H, Chen X, Zhou X, Liu J, Rodríguez AF, González-Colmenero AD, Wang Y, Li L, Sutanto S, Solis RC, Díaz González-Colmenero F, Rodriguez-Gutierrez R, Walsh M, Guyatt G, Strippoli GFM
doi: 10.1136/bmj.m4573
Cardiovascular Risk and Diseases
Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Cardiovascular Disease: A Review
JAMA Cardiol.
Honigberg MC, Chang LS, McGuire DK, Plutzky J, Aroda VR, Vaduganathan M
doi: 10.1001/jamacardio.